|Study Type:||Phase IIb|
|Stage:||Follow-up (closed to accrual)|
|Study Start Date:||2016-03-31|
|Study Made Public:||NA|
A Phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men
HVTN 704/HPTN 085 (AMP study) is a Phase IIb clinical trial to evaluate the safety and immunogenicity of VRC-HIVMAB060-00-AB (VRC01 mAb).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.